{"hands_on_practices": [{"introduction": "This first exercise explores the bedrock principle of pharmacology: a drug's effect is mediated through its interaction with a specific molecular target. We will use a classic thought experiment involving a genetically modified organism to test this idea. By considering a mouse model that lacks the primary receptor for morphine, the mu-opioid receptor, you can predict the outcome of drug administration and solidify your understanding of the essential relationship between a ligand and its receptor [@problem_id:2346911].", "problem": "In the field of molecular neuroscience, researchers often use genetically modified organisms to study the function of specific proteins. A team of scientists has created a line of \"knockout\" mice that lack a functional gene for the mu-opioid receptor, designated as the Opioid Receptor Mu 1 (*OPRM1*) gene. This receptor is known to be expressed in key areas of the central nervous system involved in pain modulation.\n\nThese knockout mice are physiologically normal in other respects. To investigate the role of the mu-opioid receptor in pain relief, the researchers administer a standard dose of morphine, a well-known analgesic compound, to both the knockout mice and a control group of wild-type (genetically normal) mice. Analgesia is defined as the reduction in the sensation of pain.\n\nBased on the principles of drug-receptor interaction, what is the most likely outcome regarding the analgesic effect of morphine in the *OPRM1* knockout mice compared to the wild-type mice?\n\nA. The knockout mice will experience a greatly enhanced and prolonged analgesic effect.\n\nB. The analgesic effect in the knockout mice will be indistinguishable from that in the wild-type mice.\n\nC. The knockout mice will experience a paradoxical increase in pain sensitivity (hyperalgesia).\n\nD. The knockout mice will show a significantly reduced or completely absent analgesic effect.", "solution": "Define morphine as ligand $D$ and the target receptor as $R$ (the product of the OPRM1 gene). The fundamental drug-receptor interaction is described by the reversible binding equilibrium\n$$\nD + R \\rightleftharpoons DR,\n$$\nwith dissociation constant\n$$\nK_{D} = \\frac{[D][R]}{[DR]}.\n$$\nLet the total receptor concentration be $[R_{t}] = [R] + [DR]$. Under the standard receptor theory (law of mass action with the usual approximation that $[D]$ is not depleted by binding), the concentration of drug-receptor complex is\n$$\n[DR] = \\frac{[D][R_{t}]}{K_{D} + [D]}.\n$$\nThe pharmacological effect $E$ for an agonist is proportional to the concentration of the active complex, with proportionality constant given by intrinsic efficacy $\\alpha$ and the transduction factor $k$, so one can write\n$$\nE = k \\alpha [DR] = k \\alpha \\frac{[D][R_{t}]}{K_{D} + [D]}.\n$$\nIn wild-type mice, $[R_{t}] > 0$, so administration of morphine ($[D] > 0$) yields $[DR] > 0$ and hence $E > 0$, i.e., an analgesic effect.\n\nIn OPRM1 knockout mice, by construction there is no functional receptor, so\n$$\n[R_{t}] = 0.\n$$\nSubstituting into the binding and effect equations gives\n$$\n[DR] = \\frac{[D]\\cdot 0}{K_{D} + [D]} = 0 \\quad \\Rightarrow \\quad E = k \\alpha \\cdot 0 = 0.\n$$\nThus, irrespective of the administered dose within the usual range, morphine cannot form the required drug-receptor complex and cannot produce its receptor-mediated analgesic response. While other opioid receptor subtypes exist, morphineâ€™s clinically relevant analgesia is mediated predominantly through the OPRM1-encoded receptor; therefore, the analgesic effect will be significantly reduced or absent in the knockout mice compared to wild-type.\n\nConsequently, the most likely outcome is a significantly reduced or completely absent analgesic effect.", "answer": "$$\\boxed{D}$$", "id": "2346911"}, {"introduction": "Building on the concept of the drug-receptor interaction, we now delve into a more nuanced view of receptor function. Receptors are not always passive entities waiting for a ligand; some exhibit 'constitutive activity,' meaning they can signal even in the absence of an agonist. This exercise presents experimental data from a system with a constitutively active kappa-opioid receptor and challenges you to classify an unknown compound, introducing the important pharmacological concept of an inverse agonist [@problem_id:2346851].", "problem": "The kappa-opioid receptor (KOR) is a G-protein coupled receptor (GPCR) predominantly found in the central nervous system. It primarily couples to the inhibitory Gi/o family of G-proteins. The activation of the Gi/o signaling pathway by KOR leads to the inhibition of the enzyme adenylyl cyclase, which in turn causes a reduction in the intracellular concentration of the second messenger, cyclic Adenosine Monophosphate (cAMP).\n\nA key feature of the KOR system is that it exhibits significant constitutive, or ligand-independent, activity. This means that a notable fraction of the receptors exists in an active conformational state even in the complete absence of any binding ligand.\n\nA pharmaceutical laboratory is investigating a novel synthetic compound, designated \"Compound Z\", for its potential interaction with KORs. They use a cultured cell line that has been genetically engineered to express a high density of human KORs. The intracellular cAMP concentration is measured under several conditions. The following observations are recorded:\n\n1.  A control group of cells, which do not express KORs, has a baseline intracellular cAMP concentration defined as $C_{base}$.\n2.  The KOR-expressing cells, in the absence of any added compounds, exhibit a steady-state cAMP concentration of $C_{const}$, which is measured to be significantly lower than $C_{base}$.\n3.  Upon addition of Compound Z to the KOR-expressing cells, the intracellular cAMP concentration changes, reaching a new steady-state value of $C_{final}$. This final concentration is observed to be approximately equal to $C_{base}$ and thus significantly higher than $C_{const}$.\n\nBased on these experimental observations, which of the following pharmacological classifications best describes Compound Z at the kappa-opioid receptor?\n\nA. Agonist\n\nB. Partial Agonist\n\nC. Competitive Antagonist\n\nD. Inverse Agonist\n\nE. Allosteric Modulator with no intrinsic efficacy", "solution": "We model KOR signaling using the two-state receptor framework in which receptors exist in an inactive state $R$ and an active state $R^*$. Constitutive activity means that, even without ligand, a nonzero fraction of receptors occupies $R^*$, producing signaling. For a Gi/o-coupled receptor such as KOR, activation of $R^*$ inhibits adenylyl cyclase, thereby reducing intracellular cAMP.\n\nLet $C_{base}$ denote the steady-state cAMP concentration in cells without KOR, determined by endogenous adenylyl cyclase and phosphodiesterase activities without KOR-dependent inhibition. In KOR-expressing cells with constitutive activity, let the fraction of active receptors be $f_{const} > 0$ in the absence of ligand. Because Gi/o activation inhibits adenylyl cyclase, the steady-state cAMP is reduced relative to $C_{base}$; this is observed as $C_{const}  C_{base}$.\n\nIntroduce a ligand with intrinsic efficacy parameter $\\epsilon$:\n- If $\\epsilon > 0$ (agonist or partial agonist), the ligand stabilizes $R^*$, increasing receptor activity above the constitutive level and further enhancing Gi/o-mediated inhibition of adenylyl cyclase. This would decrease cAMP from $C_{const}$, predicting $C_{final}  C_{const}$, which contradicts the observation that $C_{final} \\approx C_{base} > C_{const}$.\n- If $\\epsilon = 0$ (neutral competitive antagonist), the ligand has equal affinity for $R$ and $R^*$ and does not shift the $R/R^*$ equilibrium. In the absence of an orthosteric agonist, this produces no change in constitutive signaling, predicting $C_{final} = C_{const}$, which again contradicts the observation $C_{final} \\approx C_{base} > C_{const}$.\n- If $\\epsilon  0$ (inverse agonist), the ligand stabilizes $R$ relative to $R^*$, reducing constitutive receptor activity. For a Gi/o-coupled receptor, this reduces the inhibition of adenylyl cyclase, thereby increasing cAMP toward the value without KOR signaling. In symbols, if the inhibitory effect on adenylyl cyclase is proportional to active receptor level, one can write a steady-state relation such as $C = C_{base} - \\alpha A$, where $\\alpha > 0$ and $A$ is the effective activity due to KOR. In control cells without KOR, $A=0$ and $C=C_{base}$. In constitutively active KOR-expressing cells, $A = A_{const} > 0$ and $C = C_{const}  C_{base}$. Upon adding an inverse agonist, $A$ decreases toward $0$, yielding $C_{final} \\to C_{base}$. This matches the observation $C_{final} \\approx C_{base}$ and $C_{final} \\gg C_{const}$.\n\nAn allosteric modulator with no intrinsic efficacy would not change basal constitutive signaling in the absence of an orthosteric ligand and therefore would not raise $C_{const}$ to $C_{base}$.\n\nTherefore, the only classification consistent with $C_{final} \\approx C_{base} > C_{const}$ in a system with constitutive Gi/o-coupled KOR activity is that Compound Z is an inverse agonist at KOR.", "answer": "$$\\boxed{D}$$", "id": "2346851"}, {"introduction": "Our final practice bridges the gap between molecular pharmacology and cellular neurophysiology. The activation of an opioid receptor initiates a cascade of intracellular events, often culminating in a change to the neuron's electrical properties. This problem asks you to analyze electrophysiological data to quantify the effect of an opioid peptide on a specific ion channel, the G-protein-gated inwardly rectifying potassium (GIRK) channel. By calculating the channel conductance from voltage-clamp recordings, you will directly measure the downstream consequence of opioid receptor signaling [@problem_id:2346864].", "problem": "A neurophysiologist is investigating the modulatory effects of opioid peptides on neurons in the arcuate nucleus of the hypothalamus. The experiment uses the whole-cell voltage-clamp technique to measure ion currents. The internal pipette solution contains a potassium concentration, $[K^{+}]_{in}$, of 140 mM, while the external bath solution has a potassium concentration, $[K^{+}]_{out}$, of 5 mM. To isolate potassium currents, voltage-gated sodium channels are blocked with tetrodotoxin (TTX) and voltage-gated calcium channels are blocked with cadmium chloride ($\\text{CdCl}_2$).\n\nThe neuron is held at a constant membrane potential of -60 mV. To measure current, the voltage is stepped to a test potential, $V_{test}$, of -100 mV. The experiment records the steady-state current at this test potential under two conditions:\n1.  **Control:** Before any drug application, the measured current is $I_{control} = -15$ pA.\n2.  **Drug Application:** After applying a saturating concentration of dynorphin A, a peptide that activates G-protein-gated inwardly rectifying potassium (GIRK) channels, the new steady-state current is $I_{dynorphin} = -185$ pA.\n\nAssume the experiment is conducted at a temperature of $300$ K. Use the following constants: the ideal gas constant $R = 8.314 \\text{ J/(mol}\\cdot\\text{K)}$, the Faraday constant $F = 96485 \\text{ C/mol}$, and the valence of a potassium ion $z = +1$.\n\nCalculate the specific conductance of the population of dynorphin-activated GIRK channels at the test potential of -100 mV. Express your answer in nanosiemens (nS), rounded to two significant figures.", "solution": "Because voltage-gated $\\text{Na}^+$ and $\\text{Ca}^{2+}$ channels are blocked, the remaining voltage-dependent steady current is carried predominantly by $K^{+}$. For a $K^{+}$-selective conductance, the current at membrane potential V is given by Ohmâ€™s law for channels:\n$$\nI = g\\,(V - E_{K}),\n$$\nwhere g is the $K^{+}$ conductance and $E_{K}$ is the Nernst equilibrium potential for $K^{+}$.\n\nFirst, compute $E_{K}$ using the Nernst equation:\n$$\nE_{K} = \\frac{RT}{zF}\\ln\\!\\left(\\frac{[K^{+}]_{out}}{[K^{+}]_{in}}\\right).\n$$\nWith $R=8.314\\,\\text{J/(mol}\\cdot\\text{K)}$, $T=300\\,\\text{K}$, $F=96485\\,\\text{C/mol}$, $z=+1$, $[K^{+}]_{out}=5\\,\\text{mM}$, and $[K^{+}]_{in}=140\\,\\text{mM}$,\n$$\n\\frac{RT}{F} = \\frac{8.314\\times 300}{96485}\\,\\text{V} \\approx 2.585\\times 10^{-2}\\,\\text{V},\n$$\n$$\n\\ln\\!\\left(\\frac{5}{140}\\right) = \\ln\\!\\left(\\frac{1}{28}\\right) = -\\ln(28) \\approx -3.3322,\n$$\nso\n$$\nE_{K} \\approx \\left(2.585\\times 10^{-2}\\,\\text{V}\\right)\\left(-3.3322\\right) \\approx -8.61\\times 10^{-2}\\,\\text{V} = -86.1\\times 10^{-3}\\,\\text{V}.\n$$\n\nThe dynorphin-activated GIRK current is the drug-induced change in current at the test potential:\n$$\nI_{\\text{GIRK}} = I_{\\text{dynorphin}} - I_{\\text{control}} = (-185 - (-15))\\,\\text{pA} = -170\\,\\text{pA} = -170\\times 10^{-12}\\,\\text{A}.\n$$\n\nAt the test potential $V_{\\text{test}}=-100\\,\\text{mV}=-100\\times 10^{-3}\\,\\text{V}$, the driving force is\n$$\nV_{\\text{test}} - E_{K} = \\left(-100\\times 10^{-3}\\right) - \\left(-86.1\\times 10^{-3}\\right)\\,\\text{V} = -13.9\\times 10^{-3}\\,\\text{V}.\n$$\nThus the GIRK conductance is\n$$\ng_{\\text{GIRK}} = \\frac{I_{\\text{GIRK}}}{V_{\\text{test}} - E_{K}} = \\frac{-170\\times 10^{-12}\\,\\text{A}}{-13.9\\times 10^{-3}\\,\\text{V}} \\approx 12.23\\times 10^{-9}\\,\\text{S}.\n$$\n\nConverting to nanosiemens and rounding to two significant figures:\n$$\ng_{\\text{GIRK}} \\approx 12\\,\\text{nS}.\n$$", "answer": "$$\\boxed{12}$$", "id": "2346864"}]}